Contributions
Abstract: PB1862
Type: Publication Only
Background
The given data of fundamental studies of apoptosis processes in B-CLL testifies about the complexity and variety of mechanisms affecting the kinetics of normal cells and tumor lymphocytes in this disease. It is important to study the severity of clinical manifestations of the disease depending on the expression of the genes that modulate apoptosis.
Aims
The aim of the study is to compare the activity of genes encoding apoptosis modulators, the cell cycle and cancer-testicular PRAME protein with clinical manifestations of the disease in primary patients with B-CLL.
Methods
The level of expression of the proapoptotic genes FAS, TRAIL, TNFR2, DR4/5 and DR3, as well as the HSP27, XIAP genes, blocking apoptosis was determined in 23 patients with newly diagnosed chronic B-cell lymphocytic leukemia (B-CLL). In addition, expression of genes TP53 and P21 and cancer-testis gene PRAME are tested.
Results
According to the multivariate regression analysis, the FAS gene expression in the onset of the disease had the greatest impact on the clinical characteristics of the disease. In this connection, the patients were divided into groups with normal (group) and low gene level (group II). A low level of FAS expression (Me 387%) was associated with stage II disease (p=0,03), a large number of lymphocytes (p=0,001), fewer erythrocytes (p=0,08), and a lower level of TNFR2 gene expression (p=0,08), high level of expression of XIAP, HSP27, P21. Overall, the anti-apoptotic potential in Group II patients was higher, which was accompanied by more pronounced clinical manifestations of the disease.
Conclusion
The increased anti-apoptotic potential of tumor lymphocytes in newly diagnosed B-CLL is accompanied by a larger tumor mass and greater clinical and hematological manifestation of the disease.
Session topic: 5. Chronic lymphocytic leukemia and related disorders – Biology & Translational Research
Keyword(s): Apoptosis, Chronic Lymphocytic Leukemia, Gene expression profile
Abstract: PB1862
Type: Publication Only
Background
The given data of fundamental studies of apoptosis processes in B-CLL testifies about the complexity and variety of mechanisms affecting the kinetics of normal cells and tumor lymphocytes in this disease. It is important to study the severity of clinical manifestations of the disease depending on the expression of the genes that modulate apoptosis.
Aims
The aim of the study is to compare the activity of genes encoding apoptosis modulators, the cell cycle and cancer-testicular PRAME protein with clinical manifestations of the disease in primary patients with B-CLL.
Methods
The level of expression of the proapoptotic genes FAS, TRAIL, TNFR2, DR4/5 and DR3, as well as the HSP27, XIAP genes, blocking apoptosis was determined in 23 patients with newly diagnosed chronic B-cell lymphocytic leukemia (B-CLL). In addition, expression of genes TP53 and P21 and cancer-testis gene PRAME are tested.
Results
According to the multivariate regression analysis, the FAS gene expression in the onset of the disease had the greatest impact on the clinical characteristics of the disease. In this connection, the patients were divided into groups with normal (group) and low gene level (group II). A low level of FAS expression (Me 387%) was associated with stage II disease (p=0,03), a large number of lymphocytes (p=0,001), fewer erythrocytes (p=0,08), and a lower level of TNFR2 gene expression (p=0,08), high level of expression of XIAP, HSP27, P21. Overall, the anti-apoptotic potential in Group II patients was higher, which was accompanied by more pronounced clinical manifestations of the disease.
Conclusion
The increased anti-apoptotic potential of tumor lymphocytes in newly diagnosed B-CLL is accompanied by a larger tumor mass and greater clinical and hematological manifestation of the disease.
Session topic: 5. Chronic lymphocytic leukemia and related disorders – Biology & Translational Research
Keyword(s): Apoptosis, Chronic Lymphocytic Leukemia, Gene expression profile